Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tiotropium Bromide in Children and Adolescents with Asthma.

Paediatric drugs - 1 Dec 2017

Raissy Hengameh H, Kelly H William

Abstract excerpt

Evidence is emerging on the use of long-acting muscarinic antagonists (LAMAs) in the management of asthma. Tiotropium bromide (Spiriva® Respimat®) is the only LAMA approved in children and adolescents. As the use of tiotropium becomes more common in clinical practice, it is necessary to review the existing data to identify patients who may benefit from the addition of this medication to their daily asthma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Asthma
Share to Bronchodilator Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Muscarinic Antagonists

Share to Phenotype

Source

Identifiers

PMID: 28808948
DOI: 10.1007/s40272-017-0258-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tiotropium Bromide in Children and Adolescents with Asthma.PMID 28808948Read ↗

Consensus statement on the management of paediatric asthma.Semantic proximity Read ↗

The emerging role of tiotropium for patients with asthma.Semantic proximity Read ↗

Tiotropium: a new therapeutic option in asthma.Semantic proximity Read ↗

Airway smooth muscle phenotype and function: interactions with current asthma therapies.Semantic proximity Read ↗

Optimizing maintenance therapy in pediatric asthma.Semantic proximity Read ↗

Tiotropium Is Efficacious in 6- to 17-Year-Olds with Asthma, Independent of T2 PhenotypeSemantic proximity Read ↗

Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype.Semantic proximity Read ↗

Efficacy of anticholinergic drugs in asthma.Semantic proximity Read ↗

Pharmacotherapy of severe asthma.Semantic proximity Read ↗

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.Semantic proximity Read ↗

Positioning new pharmacotherapies for COPD.Semantic proximity Read ↗

Current drug therapies: relievers and preventers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.